BostonGene and LegoChem Biosciences, Inc. (LCB) announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody). BostonGene will serve as the study?s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients?

tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample. Leveraging its advanced AI and machine learning platforms, BostonGene will also deliver comprehensive analytics to identify predictive biomarkers and optimize the selection of patients most likely to benefit from treatment. Each patient?s tumor has a unique molecular fingerprint that can be identified with BostonGene?s differentiated analytic and software platforms for comprehensive, real-time, cost-efficient results to support the delivery of highly personalized cancer therapies that give patients the best chance of durable responses.